These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35629333)

  • 81. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
    Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
    Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Gut microbiota, fatty liver disease, and hepatocellular carcinoma.
    Chu H; Williams B; Schnabl B
    Liver Res; 2018 Mar; 2(1):43-51. PubMed ID: 30416839
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
    Schwabe RF; Greten TF
    J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.
    Sadeghi S; Bejjani A; Finn RS
    Surg Oncol Clin N Am; 2019 Oct; 28(4):695-715. PubMed ID: 31472914
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Immunotherapy of Hepatocellular Carcinoma.
    Heinrich B; Czauderna C; Marquardt JU
    Oncol Res Treat; 2018; 41(5):292-297. PubMed ID: 29705790
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma.
    Park R; Eshrat F; Al-Jumayli M; Saeed A; Saeed A
    Vaccines (Basel); 2020 Aug; 8(3):. PubMed ID: 32784389
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials.
    Harding JJ
    Future Oncol; 2018 Sep; 14(22):2293-2302. PubMed ID: 29663837
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Immune checkpoint inhibitors for hepatocellular carcinoma.
    El Dika I; Khalil DN; Abou-Alfa GK
    Cancer; 2019 Oct; 125(19):3312-3319. PubMed ID: 31290997
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
    Wu HJ; Chu PY
    Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
    Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
    Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Immune-Mediated Therapies for Liver Cancer.
    Aravalli RN; Steer CJ
    Genes (Basel); 2017 Feb; 8(2):. PubMed ID: 28218682
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma.
    Zheng X; Liu X; Lei Y; Wang G; Liu M
    Front Oncol; 2022; 12():824208. PubMed ID: 35251989
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Immunotherapy for hepatocellular carcinoma: Current and future.
    Johnston MP; Khakoo SI
    World J Gastroenterol; 2019 Jun; 25(24):2977-2989. PubMed ID: 31293335
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma.
    Antwi SO; Habboush YY; Chase LA; Lee DD; Patel T
    Ann Hepatol; 2018 Oct; 17(6):969-979. PubMed ID: 30600299
    [TBL] [Abstract][Full Text] [Related]  

  • 95. T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy.
    Bian J; Lin J; Long J; Yang X; Yang X; Lu X; Sang X; Zhao H
    Am J Cancer Res; 2020; 10(12):4585-4606. PubMed ID: 33415021
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Immunotherapy for Hepatocellular Carcinoma: A 2021 Update.
    Kole C; Charalampakis N; Tsakatikas S; Vailas M; Moris D; Gkotsis E; Kykalos S; Karamouzis MV; Schizas D
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33020428
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Atypical immunometabolism and metabolic reprogramming in liver cancer: Deciphering the role of gut microbiome.
    Golonka RM; Vijay-Kumar M
    Adv Cancer Res; 2021; 149():171-255. PubMed ID: 33579424
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.
    Loeuillard E; Yang J; Buckarma E; Wang J; Liu Y; Conboy C; Pavelko KD; Li Y; O'Brien D; Wang C; Graham RP; Smoot RL; Dong H; Ilyas S
    J Clin Invest; 2020 Oct; 130(10):5380-5396. PubMed ID: 32663198
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors.
    Abushukair HM; Saeed A
    World J Gastrointest Oncol; 2022 Jun; 14(6):1210-1212. PubMed ID: 35949209
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma.
    Cho SM; Esmail A; Raza A; Dacha S; Abdelrahim M
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.